drugset / Trial / NCT00390208

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

NCT00390208

Phase 2 Completed 60 enrolled Bay Area Retina Associates QLT Inc. · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.

Timeline

Start
2006-08
Primary completion
2008-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 500 ug Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal
Subject Verteporfin Other / unclassified